Last week, Curaleaf Holdings received conditional approval to list subordinate voting shares on the TSX, and this past Thursday, December 14, 2023, it began trading under the ticker symbol CURA. In light of this recent activity, today we have an exclusive interview for you featuring Chairman of Curaleaf, Boris Jordan. Boris gives us an inside look into the company’s strategic vision and plans for 2024 with Shadd Dales and Anthony Varrell.
It’s been a while since we’ve had Boris Jordan at our mic but we’re thrilled to welcome him back as we learn more about what the new year will have in store for Curaleaf. The listing to move to up-list on the TSX was part of that strategic vision for 2024.
Boris says this is a positive move for the company, moving to a more senior exchange with greater liquidity and easier access. He helps us understand the other reasons why the TSX is a great move – not necessarily for now, but for the next six to twelve months.
It has been tough navigating for cannabis companies, particularly in North America, but Boris explains how it has forced the participants in the space to work hard to clean up their balance sheets and rightsize their organization. The sentiment is that hopefully the US Federal government gets on board.
Looking outward, Boris helps us take a look at the other possibilities for 2024.The industry has several growth catalysts happening in New York, Germany, and Florida. We touch on these, and the many regulations shaping the industry in both Europe and the United States. What does the future hold in store? We’ll chat about the potential impact of adult-use in New York and Florida, journeying into the intricacies of the US market framework and the possibility of rescheduling.
It can be a tough decision to invest in the space despite regulatory challenges, but Shadd, Boris, and Anthony talk about some of the benefits of attempting to navigating the risk. Get all the details when you tune in to the full interview Curaleaf’s Boris Jordan.